BLINCYTO (blinatumomab) for injection
BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. Brand Name: BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014. FDA approved blinatumomab (brand name BLINCYTO) is not (yet) registered or available in India but on request Indian patient can buy BLINCYTO at the lowest price.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
BLINCYTO (blinatumomab) for injection
A drug used to treat adults and children with B-cell acute lymphoblastic leukemia that is in complete remission or that came back or did not get better with other anticancer treatment.
Blincyto is a medicine used to treat a blood cancer called B-precursor acute lymphoblastic leukaemia (ALL) in patients above one year of age when the cancer has come back (relapsed) or has not improved with previous treatment (refractory).
A drug used to treat adults and children with B-cell acute lymphoblastic leukemia that is in complete remission or that came back or did not get better with other anticancer treatment. It is also being studied in the treatment of other types of cancer. Blinatumomab binds to a protein called CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. Blinatumomab is a type of bispecific T-cell engager. Also called Blincyto.
Drug (Brand / Generic): PREVYMIS / blinatumomab
Current Indications: acute lymphoblastic leukemia (ALL)
Marketed by:: Amgen Inc
Approval Date: 2014
Dosage forms and strengths of BLINCYTO (blinatumomab).
For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution.
Find Reference Updates
- For BLINCYTO (blinatumomab) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.
- FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
- Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication
- FDA Grants Priority Review to Blinatumomab in Early-Stage CD19+ B-Cell ALL
- FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ BLINCYTO (blinatumomab) for injection ”. FDA approved blinatumomab (brand name BLINCYTO) is not (yet) registered or available in India but on request Indian patient can buy BLINCYTO at the lowest price. Confirmation of the order for BLINCYTO (blinatumomab) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to FDA approved blinatumomab (brand name BLINCYTO) India.
For personal use, get access to FDA approved blinatumomab (brand name BLINCYTO) India. On request, We have imported and delivered Anti-cancer medicines to following cities in India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.
BLINCYTO Sourcing & Delivery
Alleviare India specializes in sourcing and supplying BLINCYTO, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of BLINCYTO in India.
How much does BLINCYTO cost in the India?
Kindly reach out to us for BLINCYTO (blinatumomab) for injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import BLINCYTO to India?
To import blinatumomab BLINCYTO, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is BLINCYTO available in India?
BLINCYTO blinatumomab is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of BLINCYTO (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for BLINCYTO availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is blinatumomab available in India?
Yes, FDA approved blinatumomab (brand name BLINCYTO) is not (yet) registered or available in India but on request Indian patient can buy BLINCYTO at the lowest price. Alleviare will help patient / doctor to get in India.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand BLINCYTO (blinatumomab) for injection . The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to BLINCYTO (blinatumomab) for injection , they can inquire and find further information by sending their inquiries to ALS.